Whole tobacco smoke extracts to model tobacco dependence in animals

Neuroscience and Biobehavioral Reviews

Volumn 47, Issue , 2014, Pages 53-69

  Brennan, Katharine A ^a   Laugesen, Murray ^b   Truman, Penelope ^c  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b Health New Zealand Ltd   (New Zealand)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Animal models; Behavioural pharmacology; Conditioned place preference; Drug discrimination; Intra cranial self stimulation thresholds; Locomotor sensitisation; Nicotine; Self administration; Tobacco dependence; Tobacco smoke extracts

Indexed keywords

ACETALDEHYDE; AMINE OXIDASE (FLAVIN CONTAINING); ANABASINE; BETA CARBOLINE; COTININE; HARMAN; NICOTINE; NICOTINIC RECEPTOR; NORNICOTINE; SMOKE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; CONCENTRATION RESPONSE; DISEASE MODEL; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; DRUG DISCRIMINATION TEST; DRUG SELF ADMINISTRATION; ENZYME INHIBITION; EXPOSURE; INTERMETHOD COMPARISON; LOCOMOTION; NERVE STIMULATION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SELF ADMINISTRATION TEST; SELF STIMULATION; SENSITIZATION; SEROTONINERGIC SYSTEM; TOBACCO; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; ANIMAL; SMOKE; TOBACCO USE DISORDER;

ANIMALS; DISEASE MODELS, ANIMAL; NICOTINE; SELF ADMINISTRATION; SMOKE; TOBACCO; TOBACCO USE DISORDER;

EID: 84905816742     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.07.014     Document Type: Review

References (252)

1. Abercrombie E.D., Keefe K.A., DiFrischia D.S., Zigmond M.J. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 1989, 52:1655-1658.
2. Adell A., Biggs T.A., Myers R.D. Action of harman (1-methyl-beta-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 1996, 35:1101-1107.
3. Ambrose V., Miller J.H., Dickson S.J., Hampton S., Truman P., Lea R.A., Fowles J. Tobacco particulate matter is more potent than nicotine at upregulating nicotinic receptors on SH-SY5Y cells. Nicotine. Tob. Res. 2007, 9:793-799.
4. Aricioglu F., Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann. N.Y. Acad. Sci. 2003, 1009:196-201.
5. Arizzi M.N., Correa M., Betz A.J., Wisniecki A., Salamone J.D. Behavioral effects of intraventricular injections of low doses of ethanol, acetaldehyde, and acetate in rats: studies with low and high rate operant schedules. Behav. Brain Res. 2003, 147:203-210.
6. Attwood A.S., Penton-Voak I.S., Goodwin C., Munafo M.R. Effects of acute nicotine and alcohol on the rating of attractiveness in social smokers and alcohol drinkers. Drug Alcohol Depend. 2012, 125:43-48.
7. Ball K.T., Klein J.E., Plocinski J.A., Slack R. Behavioral sensitization to 3,4-methylenedioxymethamphetamine is long-lasting and modulated by the context of drug administration. Behav. Pharmacol. 2011, 22:847-850.
8. Barbeau A.M., Burda J., Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict. Sci. Clin. Pract. 2013, 8:5.
9. Bardo M.T., Bevins R.A., Klebaur J.E., Crooks P.A., Dwoskin L.P. (-)-Nornicotine partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacol. Biochem. Behav. 1997, 58:1083-1087.
10. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berl) 1999, 146:290-296.
11. Baum S.S., Hill R., Rommelspacher H. Norharman-induced changes of extracellular concentrations of dopamine in the nucleus accumbens of rats. Life Sci. 1995, 56:1715-1720.
12. Baum S.S., Hill R., Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur. J. Pharmacol. 1996, 314:75-82.
13. Bell K., Keane H. Nicotine control: e-cigarettes, smoking and addiction. Int. J. Drug Policy 2012, 23:242-247.
14. Belluzzi J.D., Lee A.G., Oliff H.S., Leslie F.M. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. Psychopharmacology (Berl) 2004, 174:389-395.
15. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712.
16. Benowitz N.L. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N. Engl. J. Med. 1988, 319:1318-1330.
17. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 2009, 49:57-71.
18. Bespalov A., Lebedev A., Panchenko G., Zvartau E. Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. Eur. Neuropsychopharmacol. 1999, 9:377-383.
19. Biala G., Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur. J. Pharmacol. 2006, 537:85-93.
20. Borland R., Partos T.R., Yong H.H., Cummings K.M., Hyland A. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control Four Country cohort survey. Addiction 2012, 107:673-682.
21. Brennan K.A., Crowther A., Putt F., Roper V., Waterhouse U., Truman P. Tobacco particulate matter self-administration in rats: differential effects of tobacco type. Addict. Biol. 2013, 10.1111/adb.12099.
22. Brennan K.A., Lea R.A., Fitzmaurice P.S., Truman P. Nicotinic receptors and stages of nicotine dependence. J. Psychopharmacol. 2010, 24:793-808.
23. Brennan K.A., Putt F., Roper V., Waterhouse U., Truman P. Nicotine and tobacco particulate self-administration: effects of mecamylamine, SCH23390 and ketanserin pretreatment. Curr. Psychopharmacol. 2013, 2:229-240.
24. Brennan K.A., Putt F., Truman P. Nicotine-, tobacco particulate matter- and methamphetamine-produced locomotor sensitisation in rats. Psychopharmacology (Berl) 2013, 228:659-672.
25. Breyer-Pfaff U., Wiatr G., Stevens I., Gaertner H.J., Mundle G., Mann K. Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Life Sci. 1996, 58:1425-1432.
26. Brioni J.D., Kim D.J., O'Neill A.B., Williams J.E., Decker M.W. Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res. 1994, 643:1-9.
27. Brower V.G., Fu Y., Matta S.G., Sharp B.M. Rat strain differences in nicotine self-administration using an unlimited access paradigm. Brain Res. 2002, 930:12-20.
28. Bruijnzeel A.W., Rodrick G., Singh R.P., Derendorf H., Bauzo R.M. Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats. Pharmacol. Biochem. Behav. 2011, 100:109-118.
29. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J. Neurosci. 2001, 21:1819-1829.
30. Bullen C., McRobbie H., Thornley S., Glover M., Lin R., Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob. Control 2010, 19:98-103.
31. Bullen C., Howe C., Laugesen M., McRobbie H., Parag V., Williman J., Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013, 382:1629-1637.
32. Cacace S., Plescia F., Barberi I., Cannizzaro C. Acetaldehyde oral self-administration: evidence from the operant-conflict paradigm. Alcohol. Clin. Exp. Res. 2012, 36:1278-1287.
33. Caille S., Clemens K., Stinus L., Cador M. Modeling nicotine addiction in rats. Methods Mol. Biol. 2012, 829:243-256.
34. Calderan L., Chiamulera C., Marzola P., Fabene P.F., Fumagalli G.F., Sbarbati A. Sub-chronic nicotine-induced changes in regional cerebral blood volume and transversal relaxation time patterns in the rat: a magnetic resonance study. Neurosci Lett. 2005, 377:195-199.
35. Cao J., Belluzzi J.D., Loughlin S.E., Keyler D.E., Pentel P.R., Leslie F.M. Acetaldehyde, a major constituent of tobacco smoke, enhances behavioral, endocrine, and neuronal responses to nicotine in adolescent and adult rats. Neuropsychopharmacology 2007, 32:2025-2035.
36. Cappendijk S.L., Fekkes D., van Dalen A., Pepplinkhuizen L. The acute effects of norharman on cocaine self-administration and sensorimotor function in male Wistar rats. Eur. Neuropsychopharmacol. 2001, 11:233-239.
37. Carboni E., Bortone L., Giua C., Di Chiara G. Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend. 2000, 58:93-102.
38. Carey R.J., Depalma G., Damianopoulos E., Muller C.P., Huston J.P. The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 2004, 177:46-54.
39. Carlson J.N., Fitzgerald L.W., Keller R.W., Glick S.D. Side and region dependent changes in dopamine activation with various durations of restraint stress. Brain Res. 1991, 550:313-318.
40. Carr L.A., Basham J.K., Rowell P.P. Inhibition of dopamine uptake in striatal synaptosomes by tobacco smoke fractions. Posters Neurosci. 1991, 1:99-101.
41. Carr L.A., Rowell P.P., Pierce W.M. Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochem. Res. 1989, 14:511-515.
42. Chaudhri N., Caggiula A.R., Donny E.C., Booth S., Gharib M., Craven L., Palmatier M.I., Liu X., Sved A.F. Self-administered and noncontingent nicotine enhance reinforced operant responding in rats: impact of nicotine dose and reinforcement schedule. Psychopharmacology (Berl) 2007, 190:353-362.
43. Chaudhri N., Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Sved A.F. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl) 2006, 184:353-366.
44. Chiamulera C., Borgo C., Falchetto S., Valerio E., Tessari M. Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (Berl) 1996, 127:102-107.
45. Clarke P.B., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 1985, 348:355-358.
46. Clarke P.B., Schwartz R.D., Paul S.M., Pert C.B., Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J. Neurosci. 1985, 5:1307-1315.
47. Clemens K.J., Caille S., Cador M. The effects of response operandum and prior food training on intravenous nicotine self-administration in rats. Psychopharmacology (Berl) 2010, 211:43-54.
48. Clemens K.J., Caille S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int. J. Neuropsychopharmacol. 2009, 12:1355-1366.
49. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, 30:145-155.
50. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 2002, 13:451-463.
51. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989, 99:473-478.
52. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992, 107:285-289.
53. Costello M.R., Reynaga D.D., Mojica C.Y., Zaveri N.T., Belluzi J.D., Leslie F.M. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology 2014, 10.1038/npp.2014.31.
54. Cox B.M., Goldstein A., Nelson W.T. Nicotine self-administration in rats. Br. J. Pharmacol. 1984, 83:49-55.
55. Creese I., Sibley D.R. Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol. 1981, 21:357-391.
56. Dani J.A., Balfour D.J. Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci. 2011, 34:383-392.
57. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 2001, 70:439-446.
58. Dani J.A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996, 16:905-908.
59. Danielson K., Putt F., Truman P., Kivell B.M. The effects of nicotine and tobacco particulate matter on dopamine uptake in the rat brain. Synapse 2014, 68:45-60.
60. Dawkins L., Turner J., Hasna S., Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict. Behav. 2012, 37:970-973.
61. De Deurwaerdere P., Navailles S., Berg K.A., Clarke W.P., Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 2004, 24:3235-3241.
62. De Deurwaerdere P., Stinus L., Spampinato U. Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J. Neurosci. 1998, 18:6528-6538.
63. De La Garza R., Cunningham K.A. The effects of the 5-hydroxytryptamine(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. J. Pharmacol. Exp. Ther. 2000, 292:610-617.
64. Desai R.I., Barber D.J., Terry P. Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine. Behav. Pharmacol. 1999, 10:647-656.
65. Desai R.I., Barber D.J., Terry P. Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology (Berl) 2003, 167:335-343.
66. Desai R.I., Bergman J. Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds. J. Pharmacol. Exp. Ther. 2010, 335:807-816.
67. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393:295-314.
68. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Nat. Acad. Sci. U.S.A. 1988, 85:5274-5278.
69. Di Matteo V., Di Giovanni G., Di Mascio M., Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin2C receptors. Brain Res. 2000, 865:85-90.
70. DiFranza J.R., Wellman R.J. Sensitization to nicotine: how the animal literature might inform future human research. Nicotine. Tob. Res. 2007, 9:9-20.
71. Ding Y.S., Zhang L., Jain R.B., Jain N., Wang R.Y., Ashley D.L., Watson C.H. Levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons in mainstream smoke from different tobacco varieties. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3366-3371.
72. Donny E.C., Caggiula A.R., Knopf S., Brown C. Nicotine self-administration in rats. Psychopharmacology (Berl) 1995, 122:390-394.
73. Donny E.C., Caggiula A.R., Mielke M.M., Booth S., Gharib M.A., Hoffman A., Maldovan V., Shupenko C., McCallum S.E. Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 1999, 147:135-142.
74. Donny E.C., Caggiula A.R., Mielke M.M., Jacobs K.S., Rose C., Sved A.F. Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency. Psychopharmacology (Berl) 1998, 136:83-90.
75. Dworkin S.I., Co C., Smith J.E. Rat brain neurotransmitter turnover rates altered during withdrawal from chronic cocaine administration. Brain Res. 1995, 682:116-126.
76. Dwoskin L.P., Buxton S.T., Jewell A.L., Crooks P.A. S(-)-nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. J. Neurochem. 1993, 60:2167-2174.
77. Dwoskin L.P., Crooks P.A., Teng L., Green T.A., Bardo M.T. Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine. Psychopharmacology (Berl) 1999, 145:442-451.
78. Dwoskin L.P., Teng L., Buxton S.T., Crooks P.A. (S)-(-)-cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther. 1999, 288:905-911.
79. Dwoskin L.P., Teng L., Buxton S.T., Ravard A., Deo N., Crooks P.A. Minor alkaloids of tobacco release [3H]dopamine from superfused rat striatal slices. Eur. J. Pharmacol. 1995, 276:195-199.
80. Engberg G., Erhardt S., Sharp T., Hajos M. Nicotine inhibits firing activity of dorsal raphe 5-HT neurones in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:41-45.
81. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998, 393:76-79.
82. Ergene E., Schoener E.P. Effects of harmane (1-methyl-beta-carboline) on neurons in the nucleus accumbens of the rat. Pharmacol. Biochem. Behav. 1993, 44:951-957.
83. Eriksen M., Mackay J., Ross H. The Tobacco Atlas 2012, http://www.tobaccoatlas.org (accessed March 2014). Revised fourth ed.
84. Fekkes D., Bode W.T. Occurrence and partition of the beta-carboline norharman in rat organs. Life Sci. 1993, 52:2045-2054.
85. Feltenstein M.W., Ghee S.M., See R.E. Nicotine self-administration and reinstatement of nicotine-seeking in male and female rats. Drug Alcohol Depend. 2012, 121:240-246.
86. Fletcher P.J., Le A.D., Higgins G.A. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog. Brain Res. 2008, 172:361-383.
87. Foddai M., Dosia G., Spiga S., Diana M. Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 2004, 29:530-536.
88. Forey B.A., Thornton A.J., Lee P.N. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm. Med. 2011, 11:36.
89. Fowler J.S., Volkow N.D., Logan J., Pappas N., King P., MacGregor R., Shea C., Garza V., Gatley S.J. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci. 1998, 63:PL19-PL23.
90. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379:733-736.
91. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Wolf A.P., Warner D., Cilento R., Zezulkova I. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J. Addict. Dis. 1998, 17:23-34.
92. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Nat. Acad. Sci. U.S.A. 1996, 93:14065-14069.
93. Gerard N., Ceccarini J., Bormans G., Vanbilloen B., Casteels C., Goffin K., Bosier B., Lambert D.M., Van Laere K. Influence of chronic nicotine administration on cerebral type 1 cannabinoid receptor binding: an in vivo micro-PET study in the rat using [18F]MK-9470. J. Mol. Neurosci. 2010, 42:162-167.
94. Glantz S., Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet 2012, 379:1269-1271.
95. Goldberg S.R., Risner M.E., Stolerman I.P., Reavill C., Garcha H.S. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology (Berl) 1989, 97:295-302.
96. Goniewicz M.L., Lingas E.O., Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an Internet survey. Drug Alcohol Rev. 2013, 32:133-140.
97. Gozzi A., Schwarz A., Reese T., Bertani S., Crestan V., Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat. Neuropsychopharmacology 2006, 31:1690-1703.
98. Grabus S.D., Martin B.R., Brown S.E., Damaj M.I. Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) 2006, 184:456-463.
99. Green T.A., Brown R.W., Phillips S.B., Dwoskin L.P., Bardo M.T. Locomotor stimulant effects of nornicotine: role of dopamine. Pharmacol. Biochem. Behav. 2002, 74:87-94.
100. Guillem K., Vouillac C., Azar M.R., Parsons L.H., Koob G.F., Cador M., Stinus L. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur. J. Neurosci. 2006, 24:3532-3540.
101. Hanson H.M., Ivester C.A., Morton B.R. Nicotine self-administration in rats. NIDA Res. Monogr. 1979, 70-90.
102. Harris A.C., Mattson C., Lesage M.G., Keyler D.E., Pentel P.R. Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol. Biochem. Behav. 2010, 96:217-227.
103. Harris A.C., Pentel P.R., LeSage M.G. Correlates of individual differences in compensatory nicotine self-administration in rats following a decrease in nicotine unit dose. Psychopharmacology (Berl) 2009, 205:599-611.
104. Harris A.C., Stepanov I., Pentel P.R., Lesage M.G. Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats. Psychopharmacology (Berl) 2012, 220:565-576.
105. Hawkins J., Hollingworth W., Campbell R. Long-term smoking relapse: a study using the british household panel survey. Nicotine. Tob. Res. 2010, 12:1228-1235.
106. Herraiz T. Identification and occurrence of the bioactive beta-carbolines norharman and harman in coffee brews. Food Addit. Contam. 2002, 19:748-754.
107. Herraiz T. Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Addit. Contam. 2004, 21:1041-1050.
108. Herraiz T., Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 2005, 326:378-386.
109. Hilario M.R., Turner J.R., Blendy J.A. Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology 2012, 37:2661-2670.
110. Hoffman A.C., Evans S.E. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine. Tob. Res. 2013, 15:622-632.
111. Hoffmann D., Hoffmann I., El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem. Res. Toxicol. 2001, 14:767-790.
112. Huang H.Y., Hsieh S.H. Analyses of tobacco alkaloids by cation-selective exhaustive injection sweeping microemulsion electrokinetic chromatography. J. Chromatogr. A 2007, 1164:313-319.
113. Hughes J.R. Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine. Tob. Res. 2007, 9:329-339.
114. Husbands S.M., Glennon R.A., Gorgerat S., Gough R., Tyacke R., Crosby J., Nutt D.J., Lewis J.W., Hudson A.L. beta-carboline binding to imidazoline receptors. Drug Alcohol Depend. 2001, 64:203-208.
115. Huston-Lyons D., Sarkar M., Kornetsky C. Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide. Pharmacol. Biochem. Behav. 1993, 46:453-457.
116. Imperato A., Angelucci L., Casolini P., Zocchi A., Puglisi-Allegra S. Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res. 1992, 577:194-199.
117. Jacob P., Yu L., Shulgin A.T., Benowitz N.L. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am. J. Public Health 1999, 89:731-736.
118. Jacobs E.H., Smit A.B., de Vries T.J., Schoffelmeer A.N. Neuroadaptive effects of active versus passive drug administration in addiction research. Trends Pharmacol. Sci. 2003, 24:566-573.
119. Johnson P.M., Hollander J.A., Kenny P.J. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol. Biochem. Behav. 2008, 90:409-415.
120. Jones I.W., Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J. Neurosci. 2004, 24:11244-11252.
121. Kempsill F.E., Pratt J.A. Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine. Br. J. Pharmacol. 2000, 131:997-1003.
122. Kenny P.J., Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 2006, 31:1203-1211.
123. Kerr D.C., Owen L.D., Capaldi D.M. The timing of smoking onset, prolonged abstinence and relapse in men: a prospective study from ages 18 to 32 years. Addiction 2011, 106:2031-2038.
124. Kuklina E.V., Tong X., George M.G., Bansil P. Epidemiology and prevention of stroke: a worldwide perspective. Expert Rev. Neurother. 2012, 12:199-208.
125. Kuroki T., Meltzer H.Y., Ichikawa J. 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 2003, 972:216-221.
126. Lang W.J., Latiff A.A., McQueen A., Singer G. Self administration of nicotine with and without a food delivery schedule. Pharmacol. Biochem. Behav. 1977, 7:65-70.
127. Latiff A.A., Smith L.A., Lang W.J. Effects of changing dosage and urinary pH in rats self-administering nicotine on a food delivery schedule. Pharmacol. Biochem. Behav. 1980, 13:209-213.
128. Lau C.E., Sun L. The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. Drug Metab. Dispos. 2002, 30:254-261.
129. Laviolette S.R., van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol. Psychiatry 2003, 8:50-59. 59.
130. Laviolette S.R., van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 2004, 5:55-65.
131. Le Foll B., Chakraborty-Chatterjee M., Lev-Ran S., Barnes C., Pushparaj A., Gamaleddin I., Yan Y., Khaled M., Goldberg S.R. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int. J. Neuropsychopharmacol. 2012, 15:1265-1274.
132. Le Foll B., Goldberg S.R. Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) 2005, 178:481-492.
133. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb. Exp. Pharmacol. 2009, 192:335-367.
134. Lena C., Changeux J.P. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr. Opin. Neurobiol. 1997, 7:674-682.
135. LeSage M.G., Burroughs D., Dufek M., Keyler D.E., Pentel P.R. Reinstatement of nicotine self-administration in rats by presentation of nicotine-paired stimuli, but not nicotine priming. Pharmacol. Biochem. Behav. 2004, 79:507-513.
136. Lewis A., Miller J.H., Lea R.A. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007, 28:182-195.
137. Lewis A.J., Truman P., Hosking M.R., Miller J.H. Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type. Tob. Control 2012, 21:39-43.
138. Li S., Kim K.Y., Kim J.H., Park M.S., Bahk J.Y., Kim M.O. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci. Lett. 2004, 363:29-32.
139. Li S.P., Park M.S., Kim J.H., Kim M.O. Chronic nicotine and smoke treatment modulate dopaminergic activities in ventral tegmental area and nucleus accumbens and the gamma-aminobutyric acid type B receptor expression of the rat prefrontal cortex. J. Neurosci. Res. 2004, 78:868-879.
140. Li Z., DiFranza J.R., Wellman R.J., Kulkarni P., King J.A. Imaging brain activation in nicotine-sensitized rats. Brain Res. 2008, 1199:91-99.
141. Liu B., Chen C., Wu D., Su Q. Enantiomeric analysis of anatabine, nornicotine and anabasine in commercial tobacco by multi-dimensional gas chromatography and mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 865:13-17.
142. Liu Q., Li Z., Ding J.H., Liu S.Y., Wu J., Hu G. Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats. Brain Res. 2006, 1085:138-143.
143. Lukas R.J., Changeux J.P., Le Novere N., Albuquerque E.X., Balfour D.J., Berg D.K., Bertrand D., Chiappinelli V.A., Clarke P.B., Collins A.C., Dani J.A., Grady S.R., Kellar K.J., Lindstrom J.M., Marks M.J., Quik M., Taylor P.W., Wonnacott S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 1999, 51:397-401.
144. MacInnes N., Handley S.L. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br. J. Pharmacol. 2002, 135:1227-1234.
145. Malin D.H. Nicotine dependence: studies with a laboratory model. Pharmacol. Biochem. Behav. 2001, 70:551-559.
146. Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Kawashima H., Fukuyama H., Togashi K., Saji H. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J. Nucl. Med. 2007, 48:1829-1835.
147. Mansvelder H.D., McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000, 27:349-357.
148. Manzardo A.M., Stein L., Belluzzi J.D. Rats prefer cocaine over nicotine in a two-lever self-administration choice test. Brain Res. 2002, 924:10-19.
149. Marti F., Arib O., Morel C., Dufresne V., Maskos U., Corringer P.J., de Beaurepaire R., Faure P. Smoke extracts and nicotine, but not tobacco extracts, potentiate firing and burst activity of ventral tegmental area dopaminergic neurons in mice. Neuropsychopharmacology 2011, 36:2244-2257.
150. Marubio L.M., Gardier A.M., Durier S., David D., Klink R., Arroyo-Jimenez M.M., McIntosh J.M., Rossi F., Champtiaux N., Zoli M., Changeux J.P. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci. 2003, 17:1329-1337.
151. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardinaer P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., McCallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothernfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007, 190:269-319.
152. McCreary A.C., Bankson M.G., Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J. Pharmacol. Exp. Ther. 1999, 290:965-973.
153. Melis M., Enrico P., Peana A.T., Diana M. Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system. Eur. J. Neurosci. 2007, 26:2824-2833.
154. Mello N.K., Newman J.L. Discriminative and reinforcing stimulus effects of nicotine, cocaine, and cocaine+nicotine combinations in rhesus monkeys. Exp. Clin. Psychopharmacol. 2011, 19:203-214.
155. Mihailescu S., Palomero-Rivero M., Meade-Huerta P., Maza-Flores A., Drucker-Colin R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur. J. Pharmacol. 1998, 360:31-36.
156. Miralles A., Esteban S., Sastre-Coll A., Moranta D., Asensio V.J., Garcia-Sevilla J.A. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. Eur. J. Pharmacol. 2005, 518:234-242.
157. Morrison C.F., Stephenson J.A. The occurrence of tolerance to a central depressant effect of nicotine. Br. J. Pharmacol. 1972, 46:151-156.
158. Myers W.D., Ng K.T., Singer G. Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. Pharmacol. Biochem. Behav. 1982, 17:807-811.
159. Myers W.D., Ng K.T., Singer G., Smythe G.A., Duncan M.W. Dopamine and salsolinol levels in rat hypothalami and striatum after schedule-induced self-injection (SISI) of ethanol and acetaldehyde. Brain Res. 1985, 358:122-128.
160. Naha N., Li S.P., Yang B.C., Park T.J., Kim M.O. Time-dependent exposure of nicotine and smoke modulate ultrasubcellular organelle localization of dopamine D1 and D2 receptors in the rat caudate-putamen. Synapse 2009, 63:847-854.
161. Nisell M., Nomikos G.G., Svensson T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol. Toxicol. 1994, 75:348-352.
162. Nisell M., Nomikos G.G., Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994, 16:36-44.
163. Nordberg A., Romanelli L., Sundwall A., Bianchi C., Beani L. Effect of acute and subchronic nicotine treatment on cortical acetylcholine release and on nicotinic receptors in rats and guinea-pigs. Br. J. Pharmacol. 1989, 98:71-78.
164. O'Dell L.E., Bruijnzeel A.W., Ghozland S., Markou A., Koob G.F. Nicotine withdrawal in adolescent and adult rats. Ann. N.Y. Acad. Sci. 2004, 1021:167-174.
165. O'Dell L.E., Parsons L.H. Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J. Pharmacol. Exp. Ther. 2004, 311:711-719.
166. Okuyemi K.S., Ahluwalia J.S., Harris K.J. Pharmacotherapy of smoking cessation. Arch. Fam. Med. 2000, 9:270-281.
167. Overstreet D.H., Yamamura H.I. Receptor alterations and drug tolerance. Life Sci. 1979, 25:1865-1877.
168. Panagis G., Kastellakis A., Spyraki C., Nomikos G. Effects of methyllycaconitine (MLA), an alpha 7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology (Berl) 2000, 149:388-396.
169. Parsons L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 1993, 606:195-199.
170. Paterson N.E., Semenova S., Markou A. The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology (Berl) 2008, 198:351-362.
171. Pawlak R., Takada Y., Takahashi H., Urano T., Ihara H., Nagai N., Takada A. Differential effects of nicotine against stress-induced changes in dopaminergic system in rat striatum and hippocampus. Eur. J. Pharmacol. 2000, 387:171-177.
172. Peana A.T., Enrico P., Assaretti A.R., Pulighe E., Muggironi G., Nieddu M., Piga A., Lintas A., Diana M. Key role of ethanol-derived acetaldehyde in the motivational properties induced by intragastric ethanol: a conditioned place preference study in the rat. Alcohol. Clin. Exp. Res. 2008, 32:249-258.
173. Peana A.T., Muggironi G., Diana M. Acetaldehyde-reinforcing effects: a study on oral self-administration behavior. Front. Psychiatry 2010, 1:23.
174. Pfau W., Skog K. Exposure to beta-carbolines norharman and harman. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 802:115-126.
175. Phillips P.E., Stuber G.D., Heien M.L., Wightman R.M., Carelli R.M. Subsecond dopamine release promotes cocaine seeking. Nature 2003, 422:614-618.
176. Piasecki T.M. Relapse to smoking. Clin. Psychol. Rev. 2006, 26:196-215.
177. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., Fuxe K., Changeux J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
178. Polosa R., Caponnetto P., Morjaria J.B., Papale G., Campagna D., Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health 2011, 11:786.
179. Pratt J.A., Stolerman I.P., Garcha H.S., Giardini V., Feyerabend C. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology (Berl) 1983, 81:54-60.
180. Quertemont E., De Witte P. Conditioned stimulus preference after acetaldehyde but not ethanol injections. Pharmacol. Biochem. Behav. 2001, 68:449-454.
181. Rahman S., Zhang J., Engleman E.A., Corrigall W.A. Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study. Neuroscience 2004, 129:415-424.
182. Rauhut A.S., Neugebauer N., Dwoskin L.P., Bardo M.T. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl) 2003, 169:1-9.
183. Rauhut A.S., Zentner I.J., Mardekian S.K., Tanenbaum J.B. Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine. Physiol. Behav. 2008, 93:177-188.
184. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 1996, 66:1-11.
185. Rigotti N.A. Clinical practice. Treatment of tobacco use and dependence. N. Engl. J. Med. 2002, 346:506-512.
186. Risner M.E., Goldberg S.R. A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J. Pharmacol. Exp. Ther. 1983, 224:319-326.
187. Robinson J.H., Pritchard W.S. The role of nicotine in tobacco use. Psychopharmacology (Berl) 1992, 108:397-407.
188. Robinson T.E., Berridge K.C. Incentive-sensitization and addiction. Addiction 2001, 96:103-114.
189. Rodgman A., Perfetti T.A. The Chemical Components of Tobacco and Tobacco Smoke 2013, CRC Press, Taylor & Francis Group, Florida, USA. second ed.
190. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., Lu Y., Mansbach R.S., Mather R.J., Rovetti C.C., Sands S.B., Schaeffer E., Schulz D.W., Tingley F.D., Williams K.E. Pharmacological profile of the alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
191. Romano C., Goldstein A., Jewell N.P. Characterization of the receptor mediating the nicotine discriminative stimulus. Psychopharmacology (Berl) 1981, 74:310-315.
192. Rommelspacher H., May T., Salewski B. Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur. J. Pharmacol. 1994, 252:51-59.
193. Rommelspacher H., Meier-Henco M., Smolka M., Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 2002, 441:115-125.
194. Rose J.E. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 2006, 184:274-285.
195. Rossi S., Singer S., Shearman E., Sershen H., Lajtha A. Regional heterogeneity of nicotine effects on neurotransmitters in rat brains in vivo at low doses. Neurochem. Res. 2005, 30:91-103.
196. Rotenberg K.S., Adir J. Pharmacokinetics of nicotine in rats after multiple-cigarette smoke exposure. Toxicol. Appl. Pharmacol. 1983, 69:1-11.
197. Rotenberg K.S., Miller R.P., Adir J. Pharmacokinetics of nicotine in rats after single-cigarette smoke inhalation. J. Pharm. Sci. 1980, 69:1087-1090.
198. Ruiz-Durantez E., Ruiz-Ortega J.A., Pineda J., Ugedo L. Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett. 2001, 308:197-200.
199. Salin-Pascual R.J., Rosas M., Jimenez-Genchi A., Rivera-Meza B.L., Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Psychiatry 1996, 57:387-389.
200. Saura J., Kettler R., Da Prada M., Richards J.G. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 1992, 12:1977-1999.
201. Schenk S., Hely L., Gittings D., Lake B., Daniela E. Effects of priming injections of MDMA and cocaine on reinstatement of MDMA- and cocaine-seeking in rats. Drug Alcohol Depend. 2008, 96:249-255.
202. Schenk S., Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl) 1999, 147:285-290.
203. Schwartz A.G., Prysak G.M., Bock C.H., Cote M.L. The molecular epidemiology of lung cancer. Carcinogenesis 2007, 28:507-518.
204. Semba J., Mataki C., Yamada S., Nankai M., Toru M. Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol. Psychiatry 1998, 43:389-391.
205. Sershen H., Shearman E., Fallon S., Chakraborty G., Smiley J., Lajtha A. The effects of acetaldehyde on nicotine-induced transmitter levels in young and adult brain areas. Brain Res. Bull. 2009, 79:458-462.
206. Sharma A., Brody A.L. In vivo brain imaging of human exposure to nicotine and tobacco. Handb. Exp. Pharmacol. 2009, 192:145-171.
207. Shoaib M., Schindler C.W., Goldberg S.R. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 1997, 129:35-43.
208. Shoaib M., Sidhpura N., Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 2003, 165:405-412.
209. Shoaib M., Lowe A.S., Williams S.C. Imaging localised dynamic changes in the nucleus accumbens following nicotine withdrawal in rats. Neuroimage 2004, 22:847-854.
210. Small E., Shah H.P., Davenport J.J., Geier J.E., Yavarovich K.R., Yamada H., Sabarinath S.N., Derendorf H., Pauly J.R., Gold M.S., Bruijnzeel A.W. Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) 2010, 208:143-158.
211. Smith T.T., Levin M.E., Schassburger R.L., Buffalari D.M., Sved A.F., Donny E.C. Gradual and immedidate nicotine reduction result in similar low-dose nicotine self-administration. Nicotine. Tob. Res. 2013, 15:1918-1925.
212. Solinas M., Panlilio L.V., Justinova Z., Yasar S., Goldberg S.R. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat. Protoc. 2006, 1:1194-1206.
213. Sorge R.E., Clarke P.B. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. J. Pharmacol. Exp. Ther. 2009, 330:633-640.
214. Sorge R.E., Pierre V.J., Clarke P.B. Facilitation of intravenous nicotine self-administration in rats by a motivationally neutral sensory stimulus. Psychopharmacology (Berl) 2009, 207:191-200.
215. Spijkerman R., van den Eijnden R., van de Mheen D., Bongers I., Fekkes D. The impact of smoking and drinking on plasma levels of norharman. Eur. Neuropsychopharmacol. 2002, 12:61-71.
216. Spina L., Longoni R., Vinci S., Ibba F., Peana A.T., Muggironi G., Spiga S., Acquas E. Role of dopamine D1 receptors and extracellular signal regulated kinase in the motivational properties of acetaldehyde as assessed by place preference conditioning. Alcohol. Clin. Exp. Res. 2010, 34:607-616.
217. Stedman R.L. The chemical composition of tobacco and tobacco smoke. Chem. Rev. 1968, 68:153-207.
218. Stefanski R., Ladenheim B., Lee S.H., Cadet J.L., Goldberg S.R. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur. J. Pharmacol. 1999, 371:123-135.
219. Steketee J.D., Kalivas P.W. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 2011, 63:348-365.
220. Stepanov I., Jensen J., Hatsukami D., Hecht S.S. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine. Tob. Res. 2008, 10:1773-1782.
221. Stoker A.K., Semenova S., Markou A. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology 2008, 54:1223-1232.
222. Stolerman I.P., Garcha H.S., Pratt J.A., Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology (Berl) 1984, 84:413-419.
223. Sziraki I., Sershen H., Benuck M., Lipovac M., Hashim A., Cooper T.B., Allen D., Lajtha A. The effect of cotinine on nicotine- and cocaine-induced dopamine release in the nucleus accumbens. Neurochem. Res. 1999, 24:1471-1478.
224. Takada K., Swedberg M.D., Goldberg S.R., Katz J.L. Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys. Psychopharmacology (Berl) 1989, 99:208-212.
225. Takayama S., Uyeno E.T. Intravenous self-administration of ethanol and acetaldehyde by rats. Yakubutsu Seishin Kodo 1985, 5:329-334.
226. Talhout R., Schulz T., Florek E., van Benthem J., Wester P., Opperhuizen A. Hazardous compounds in tobacco smoke. Int. J. Environ. Res. Public Health 2011, 8:613-628.
227. Tang J., Liao Y., Deng Q., Liu T., Chen X., Wang X., Xiang X., Chen H., Hao W. Altered spontaneous activity in young chronic cigarette smokers revealed by regional homogeneity. Behav. Brain Funct. 2012, 8:44.
228. Tessari M., Valerio E., Chiamulera C., Beardsley P.M. Nicotine reinforcement in rats with histories of cocaine self-administration. Psychopharmacology (Berl) 1995, 121:282-283.
229. Touiki K., Rat P., Molimard R., Chait A., de Beaurepaire R. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl) 2005, 182:562-569.
230. Touiki K., Rat P., Molimard R., Chait A., de Beaurepaire R. Effects of tobacco and cigarette smoke extracts on serotonergic raphe neurons in the rat. Neuroreport 2007, 18:925-929.
231. Vallejo Y.F., Buisson B., Bertrand D., Green W.N. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J. Neurosci. 2005, 25:5563-5572.
232. van Amsterdam J., Talhout R., Vleeming W., Opperhuizen A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci. 2006, 79:1969-1973.
233. Van A.R., Aliatas E., Smith B.R., Amit Z. Effects of ethanol on an acetaldehyde drug discrimination with a conditioned taste aversion procedure. Alcohol 2002, 28:103-109.
234. Vaupel D.B., Stein E.A., Mukhin A.G. Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. Neuroimage 2007, 34:1352-1362.
235. Vezina P., McGehee D.S., Green W.N. Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1625-1638.
236. Villegier A.S., Blanc G., Glowinski J., Tassin J.P. Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol. Biochem. Behav. 2003, 76:267-274.
237. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 1989, 284:314-335.
238. Walters C.L., Cleck J.N., Kuo Y.C., Blendy J.A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 2005, 46:933-943.
239. Wang W., Ameno K., Jamal M., Kumihashi M., Uekita I., Ameno S., Ijiri I. Effect of direct infusion of acetaldehyde on dopamine and dopamine-derived salsolinol in the striatum of free-moving rats using a reverse microdialysis technique. Arch. Toxicol. 2007, 81:121-126.
240. Ward R.J., Colantuoni C., Dahchour A., Quertemont E., De Witte P. Acetaldehyde-induced changes in monoamine and amino acid extracellular microdialysate content of the nucleus accumbens. Neuropharmacology 1997, 36:225-232.
241. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. 2000, 292:1053-1064.
242. Wilkinson J.L., Bevins R.A. Intravenous nicotine conditions a place preference in rats using an unbiased design. Pharmacol. Biochem. Behav. 2008, 88:256-264.
243. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 1990, 11:216-219.
244. Wooters T.E., Bevins R.A., Bardo M.T. Neuropharmacology of the interoceptive stimulus properties of nicotine. Curr. Drug Abuse Rev. 2009, 2:243-255.
245. Wu W., Ashley D.L., Watson C.H. Determination of nicotine and other minor alkaloids in international cigarettes by solid-phase microextraction and gas chromatography/mass spectrometry. Anal. Chem. 2002, 74:4878-4884.
246. Yamada H., Bishnoi M., Keijzers K.F., van Tuijl I.A., Small E., Shah H.P., Bauzo R.M., Kobeissy F.H., Sabarinath S.N., Derendorf H., Bruijnzeel A.W. Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. Pharmacol. Biochem. Behav. 2010, 95:401-409.
247. Yan Q.S., Yan S.E. Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur. J. Pharmacol. 2001, 418:55-64.
248. Yin R., French E.D. A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an in vitro electrophysiological study. Brain Res. Bull. 2000, 51:507-514.
249. Yokel R.A., Piekens R. Drug level of d- and l-amphetamine during intravenous self-administration. Psychopharmacologia 1974, 34:255-264.
250. Ypsilantis P., Politou M., Anagnostopoulos C., Kortsaris A., Simopoulos C. A rat model of cigarette smoke abuse liability. Comp. Med. 2012, 62:395-399.
251. Yu P.H., Boulton A.A. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 1987, 41:675-682.
252. Zhu P.J., Chiappinelli V.A. Nicotine modulates evoked GABAergic transmission in the brain. J. Neurophysiol. 1999, 82:3041-3045.